Evista Information
What's inside Evista
Evista Active Ingredients: raloxifene hydrochloride, details.| Evista Dosages & Strengths | ||||
|---|---|---|---|---|
| Strength | Format | Route | Strength | Class |
| Evista 60 mg | tablet | oral | 1.0 each | OTC |
Recent Evista Side Effects
Posted by pepita about 1 year ago
I have been taking Evista for a year and I have had weight loss and legs cramps. I do not take any other medication. Has an...
Posted by dotjack56 over 2 years ago
Does this Evista cause Weight Gain?
Posted by al12coop over 3 years ago
I experience NO side effects.......BUT.....could taking Evista possible cause an eye condition known as "narrow angles" ?
Evista in the News
Implication of Food Allergies and Intolerances on Medication ... - Ortho SuperSite
Evista (raloxifene) [package insert]. Indianapolis, IN: Eli Lilly and Company; 2007. Boniva (ibandronate) [package insert]. ...
Tue Feb 26 11:08:05 -0500 2008
Old Drug Eases Side Effects of Prostate Cancer Treatment - Wall Street Journal
The drug, which would be marketed under the brand name Acapodene, is in the same class as breast cancer drug tamoxifen and Eli Lilly’s Evista, which is used ...
Mon Feb 25 05:43:28 -0500 2008
Examine Challenges and Opportunities in Developing Chemopreventive ... - PR-Inside.com (Pressemitteilung)
On September 13, 2007, the FDA approved Eli Lilly's Evista for chemoprevention of breast cancer in high-risk women. Why does Evista represent a major ...
Tue Feb 19 06:29:36 -0500 2008
Evista Chemical Information
raloxifene hydrochloride - The hydrochloride salt form of raloxifene, a selective benzothiophene estrogen receptor modulator (SERM) with lipid lowering effects and activity against osteoporosis. Raloxifene hydrochloride specifically binds to estrogen receptors in responsive tissue, including liver, bone, breast, and endometrium. The resulting ligand-receptor complex is translocated to the nucleus where, depending on the tissue type, it promotes or suppresses the transcription of estrogen-regulated genes, thereby exerting its agonistic or antagonistic effects. This agent functions as an estrogen agonist in lipid metabolism, thereby decreasing total and LDL cholesterol levels. In tissue like bone, it decreases bone resorption and bone turnover and increases bone mineral density. Raloxifene hydrochloride acts as an estrogen antagonist in uterine and breast tissue. This agent also exerts an anti-proliferative effect on estrogen-sensitive breast cancer.
Evista RSS Feed
